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Abstract
Introduction: Recently several diagnostic manufacturers have launched new 25-hydroxy-vitamin D (25[OH]D) assays, which are aligned to the Na-
tional Institute of Standards and Technology (NIST) Standard Reference Materials (SRM) (NIST, Gaithersburg, Maryland). The aim of this study was to 
compare the performance of one liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, one enzyme linked immunosorbent assay 
(ELISA), and one recalibrated and previous version of a chemiluminescence immunoassay (CLIA). 
Material and methods: Serum-aliquots of 198 patient samples from routine 25(OH)D analysis were measured by the ClinMass® LC-MS/MS Com-
plete Kit (RECIPE Chemicals + Instruments GmbH, Munich, Germany), the ORGENTEC 25(OH)D3/D2 ELISA (ORGENTEC Diagnostika GmbH, Mainz, Ger-
many), the recalibrated Immunodiagnostic Systems (IDS)-iSYS 25(OH)DS and the previous used IDS-iSYS 25(OH)D CLIA (Immunodiagnostic Systems 
Ltd, Boldon, United Kingdom). Bland-Altman and Deming regression analyses were calculated for methods comparison of all tested 25(OH)D assays. 
The LC-MS/MS method was defined as the reference method. Within-run and between-run precision measurements were performed for all met-
hods with three different concentration levels.
Results: Compared to the LC-MS/MS method, the new IDS-iSYS 25(OH)DS and ORGENTEC 25(OH)D3/D2 assay demonstrated mean relative biases of 
16.3% and 17.8%. The IDS-iSYS 25(OH)D assay showed the lowest mean bias of 1.5%. Deming regression analyses of the recalibrated IDS-iSYS 25(OH)
DS and the ORGENTEC 25(OH)D3/D2 assay showed proportional differences, when compared to the reference method. All assays showed a within-run 
and between-run imprecision of ≤ 20% at each of the evaluated concentration levels. 
Conclusions: The evaluated standardized immunoassays and LC-MS/MS are useful methods for measuring 25(OH)D serum-levels in clinical labora-
tories.
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The clinical interest in the physiological impor-
tance of the steroid hormone vitamin D and its 
possible roles in the pathophysiological processes 
of many diseases have increased the demand for 
the measurement of vitamin D and its metabolites 
(1). On the one hand, vitamin D deficiency results 
in abnormalities in bone metabolism known as 
rickets, osteomalacia, and osteoporosis (2,3). On 
the other hand, it is associated with non-skeletal 
diseases such as type one diabetes mellitus (2,4,5), 
multiple sclerosis (2), cancer (2,5), hypertension (5) 
or cardiovascular disease (5,6).
In the liver vitamin D is converted to the 25-hy-
droxy-vitamin D (25[OH]D) and transported in the 
circulation by the vitamin-D binding protein (DBP). 
In the kidneys the biologically active form 1,25-di-
hydroxy-vitamin D (1,25[OH]2D) is created from 
25(OH)D (7). This active form has a circulating half-
life of only 4-6 hours and serum-levels of about 
1000 fold less than 25(OH)D (1,8,9). The major cir-
culating form of vitamin D is 25(OH)D, which has a 
half-life of approximately 2-3 weeks (8). Therefore, 
the total 25(OH)D is principally used as the bio-
marker indicating the vitamin D status (9,10). 
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In the past, 25(OH)D measurements have proven 
to be a major challenge with a wide spread varia-
tion in the results (1). The sometimes huge be-
tween-method discrepancies have been known 
for many years from data obtained from the Inter-
national Vitamin D External Quality Assessment 
Scheme (DEQAS) (11-13). The DEQAS was already 
founded in 1989 and meanwhile has become the 
largest vitamin D quality assessment program 
worldwide (14). 
To overcome the problem of inter-laboratory as 
well as inter-assay discrepancies, the Vitamin D 
Standardization Program (VDSP) was established 
in 2011. This program is conducted as a collabora-
tion between the US Office of Dietary Supple-
ments (ODS) of the National Institute of Health 
(NIH), the Center for Disease Control and Preven-
tion (CDC), the National Centre for Environmental 
Health (NCEH), the National Institute of Standards 
and Technology (NIST), and the Belgian Laborato-
ry for Analytical Chemistry, Faculty of Pharmaceu-
tical Sciences, Ghent University (10,13). The NIST, in 
collaboration with the ODS, has developed and 
certificated Standard Reference Materials (SRM 
2972 and 972a) for vitamin D metabolites in hu-
man serum (10,15). 
The 3-epi-25(OH)D3 (C3-epimer) is a vitamin D me-
tabolite, which is considered as a confounder in 
25(OH)D measurements. The biological role and 
its clinical significance are still unknown. The pres-
ence of the C3-epimer is considered to affect the 
quantification of 25(OH)D3 measurements in rou-
tine LC-MS/MS methods, especially in infant popu-
lations (16). For that reason, the measurement of 
this metabolite is one important objective of the 
VDSP (10). 
The recent release of a new generation of 25(OH)D 
assays, which are aligned to the NIST SRM, is antici-
pated to show an improved analytical perfor-
mance. Considering the difficulties of 25(OH)D 
measurements in the past, the hypothesis of this 
study was, that the standardization of this new 
generation of 25(OH)D assays represents an im-
provement of inter-assay accordance in daily clini-
cal 25(OH)D determination. 
The aim of our study was to compare the previous 
version of one chemiluminescence immunoassay 
(CLIA), which is not aligned to the NIST SRM, the 
new follow-up version of this CLIA and one new 
enzyme linked immunosorbent assay (ELISA), both 
aligned to the NIST SRM 2972, and at least one 
new liquid chromatography-mass tandem spec-
trometry (LC-MS/MS) kit, which is aligned to the 
new NIST SRM 972a and able to separate and de-
tect the C3-epimer. The LC-MS/MS method was de-
fined as the reference method. The 25(OH)D meas-
urements of the new vitamin D assays were based 
on 25(OH)D2 and 25(OH)D3 detection.
Materials and methods
Subjects
For the method evaluation of the above men-
tioned 25(OH)D assays, leftover blood samples 
from routine 25(OH)D analysis of 198 patients, who 
were admitted to the General Hospital Steyr (Steyr, 
Austria), were analyzed. Blood sampling was per-
formed from August 14 to October 09, 2013 at the 
Hospital’s wards after an overnight fasting state 
(12 h). VACUETTE® Z Serum Sep Clot Activator 
tubes (4 mL) with inert separator gel (Greiner Bio-
one International GmbH, Kremsmünster, Austria) 
were used for blood draw from a peripheral vein. 
At the Institute of Laboratory Medicine the serum 
samples were centrifuged with 2200 x g for 10 
minutes, divided in aliquots and stored at -30 °C 
until the 25(OH)D measurements and precision 
studies were performed in December 2013. 
The study is in accordance with the ethical stand-
ards of the Declaration of Helsinki. The ethical ap-
proval was provided by the Ethical Committee of 
Upper Austria, Linz, Austria (trial registration num-
ber: K-39-13).
Methods
Immunodiagnostic Systems (IDS-)iSYS 25(OH)D 
assay (Immunodiagnostic Systems Ltd, Boldon, 
United Kingdom)
This automated immunoassay is the previous ver-
sion of the new follow-up IDS-iSYS 25(OH)DS CLIA 
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as listed below. It is based on chemiluminescence 
technology. The assay was performed on the IDS-
iSYS Multi-Discipline Automated Analyzer. 10 µL of 
serum aliquots were automatically pipetted and 
subjected to a pre-treatment step with NaOH (part 
of the reagent used for CLIA and ELISA methods) 
to denature the DBP inside the IDS-iSYS Multi-Dis-
cipline Automated Analyzer. The extraction proce-
dure of 25(OH)D from the DBP was followed by 
analysis. This assay is not aligned to the NIST SRM 
(NIST, Gaithersburg, Maryland). The measurement 
range of this assay is 5-140 ng/mL (information of 
the manufacturer). The IDS-iSYS 25(OH)D control 
set (IS-2730) (Immunodiagnostic Systems Ltd, 
Boldon, United Kingdom) was used for quality 
control (QC).
IDS-iSYS 25(OH)DS assay (Immunodiagnostic 
Systems Ltd, Boldon, United Kingdom) 
In December 2013, this new recalibrated version 
replaced the IDS-iSYS 25(OH)D assay on the mar-
ket. This immunoassay also was performed on the 
IDS-iSYS Multi-Discipline Automated Analyzer. Ac-
cording to the previous version of this assay, the 
denaturation of the DBP was also done with NaOH 
(part of the reagent used for CLIA and ELISA meth-
ods) inside the analyzer. In contrast, this assay is 
aligned to the NIST SRM 2972 (NIST, Gaithersburg, 
Maryland). The measurement range of this assay is 
7-125 ng/mL (information of the manufacturer). 
The IDS-iSYS 25(OH)DS Control Set (IS-2730S) (Im-
munodiagnostic Systems Ltd, Boldon, United 
Kingdom) was used for QC.
ORGENTEC 25(OH)D3/D2 assay (ORGENTEC 
Diagnostika GmbH, Mainz, Germany)
This recently launched assay is based on a com-
petitive ELISA. A single (not duplicate) serum sam-
ple was pipetted manually into well number one 
of an eight-well-micro strip. The extraction of 
25(OH)D2/D3 was done automatically inside the 
Alegria® Random Access Analyzer. Serum samples 
were mixed with tracer reagent (ORGENTEC Diag-
nostika GmbH, Mainz, Germany) and the 25(OH)
D2/D3 was delivered from the DBP. The extraction 
procedure was followed by analysis. This assay is 
also aligned to the NIST SRM 2972 (NIST, Gaithers-
burg, Maryland). The measurement range of this 
assay is 5-170 ng/mL (information of the manufac-
turer). The 25-OH Vitamin D3/D2 Control Set (OR-
GENTEC Diagnostika GmbH, Mainz, Germany) was 
used for QC.
ClinMass® LC-MS/MS Complete Kit (RECIPE 
Chemicals + Instruments GmbH, Munich, Germany)
This is a new commercially available LC-MS/MS as-
say, which is aligned to the NIST SRM 972a (NIST, 
Gaithersburg, Maryland). The sample pre-treat-
ment for precipitation was followed by LC-MS/MS 
analysis: for precipitation a 150 µL mixture of deu-
terated internal standard (IS) (25[OH]D3-d6) (RECI-
PE Chemicals + Instruments GmbH, Munich, Ger-
many) and precipitant P (aqueous salt solution) 
(RECIPE Chemicals + Instruments GmbH, Munich, 
Germany) was added to 50 µL serum samples. Af-
ter the precipitation step the clear supernatant (40 
µL) was subjected for further analysis by a Xevo 
Triple Quadrupole Mass Spectrometer (TQ-S) (Wa-
ters Corporation, Milford, Massachusetts) linked to 
an ACQUITY Ultra Performance Liquid Chromatog-
raphy (UPLC) (Waters Corporation, Milford, Massa-
chusetts). For the assessment of the vitamin D sta-
tus the kit is able to distinguish 25(OH)D2 and 
25(OH)D3 and enables the separation and qualita-
tive detection of C3-epimers in a single run. The 
measurement range of this assay is 5-250 ng/mL 
(information of the manufacturer). QC was per-
formed by the use of ClinCheck® serum controls 
(RECIPE Chemicals + Instruments GmbH, Munich, 
Germany). The performance is controlled by an ex-
ternal quality assurance program via participation 
at DEQAS three times a year. 
Precision studies of the immunoassays
The precision studies of the immunoassays were 
performed according to the EP10-A2 Guideline of 
the Clinical and Laboratory Standards Institute 
(CLSI): Preliminary Evaluation of Quantitative Clini-
cal Laboratory Methods (17). The 25-OH vitamin 
D3/D2 control set (IS-2730) (IDS-iSYS 25(OH)D as-
say), the IDS-iSYS 25(OH)DS control set (IS-2730S) 
(IDS-iSYS 25(OH)DS assay), and the 25-OH Vitamin 
D3/D2 control set (ORGENTEC 25(OH)D3/D2 assay) 
were used for precision measurements of the im-
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munoassays. According to the protocol (17), equal 
parts of the high- and low-level QC material were 
mixed to create the mid-level. At least one run per 
day at five consecutive workdays (from monday to 
friday) with a specific sequence (mid-, high-, low-, 
mid-, mid-, low-, low-, high-, high-, and mid-level) 
without change, interruption or intervening sam-
ples was analyzed for each immunoassay to deter-
mine the between-run precision (N = 5) for each 
level. In addition to the required measurements in 
the EP10-A2 protocol, one tenfold measurement 
(N = 10) of the low-, mid- and high-level of each 
immunoassay was performed at one day to deter-
mine the within-run precision.
Precision studies of the LC-MS/MS method
The precision studies of the LC-MS/MS method 
were performed according to the Guidance for In-
dustry – Bioanalytical Method Validation (18). 
Three serum pools with mixed 25(OH)D2 (25[OH]
D2 spiked serum pools: pool 1 = 10.9 ng/mL; pool 2 
= 21.0 ng/mL; pool 3 = 29.3 ng/mL) and 25(OH)D3 
(pool 1 = 9.57 ng/mL; pool 2 = 19.6 ng/mL; pool 3 
= 31.2 ng/mL) of different concentration levels 
were used to evaluate the distinction and repro-
ducibility of the 25(OH)D2 and 25(OH)D3 detection 
of this method. At least three runs per day at eight 
analytical days were measured to determine the 
between-run precision (N = 24) for each serum 
pool. An eightfold measurement of each serum 
pool at three analytical days was performed to de-
termine the within-run precision (N = 24).  
Statistical analysis
Bland-Altman and Deming regression plots were 
calculated for methods comparison of all tested 
25(OH)D assays. The LC-MS/MS method was de-
fined as the reference method. All other methods 
were compared to the reference method. Within-
run and between-run precision at each concentra-
tion level were assessed by calculating the mean, 
the standard deviation (SD) and the coefficient of 
variation (CV) of the above mentioned replicates 
and sequences. The CV was calculated based on 
the formula: CV (%) = 100 x standard deviation 
(SD)/mean (ng/mL). According to the literature (18), 
the precision goal for each concentration level for 
the within-run and between-run was not to ex-
ceed 20% of the CV. Analyse-it® software version 
2.30 (Analyse-it Software, Ltd, Leeds, United King-
dom) was used for statistical analysis. A P-value < 
0.05 was considered statistically significant.
Results
Characteristics of the study population
The study population mainly consisted of adults 
and a total of five adolescents between 15 and 19 
years. No newborns or young children were meas-
ured. Of all patients (N = 198), 57.6% (N = 114) were 
female. The median age was 63 (range: 15–91) 
years. 
Immunoassays vs. LC-MS/MS method
Bland-Altman plots are illustrated in Figure 1 A-C. 
Compared to the LC-MS/MS method, the new NI-
ST-SRM aligned IDS-iSYS 25(OH)DS and ORGENTEC 
25(OH)D3/D2 assay demonstrated mean relative bi-
ases of 16.3% and 17.8%. The IDS-iSYS 25(OH)D as-
say showed the lowest mean bias of 1.5%. Deming 
regression plots are shown in Figure 2 A–C. Ac-
cording to the author’s study, the results are as fol-
lows: IDS-iSYS 25(OH)D vs. LC-MS/MS: y = -2.16 
(-5.81 to 1.49) + 1.09 (0.96 to 1.22)x,  IDS-iSYS recali-
brated vs. LC-MS/MS: y = -1.76 (-7.33 to 3.82) + 1.23 
(1.04 to 1.42)x, and ORGENTEC vs. LC-MS/MS: y = 
-4.10 (-13.25 to 5.05) + 1.31 (1.02 to 1.61)x. A box-
and-whisker plot of all 25(OH)D assay comparisons 
is illustrated in Figure 3.
Precision studies of the immunoassays
The results of the precision studies of the immu-
noassays are demonstrated in Table 1. All immuno-
assays showed a within-run and between-run im-
precision of ≤ 20% at each concentration level 
(low, mid, high). The highest within-run CV (19.0%) 
was observed at the low-level precision measure-
ments with the IDS-iSYS 25(OH)DS assay. The high-
est between-run CV (19.1%) was shown at the low-
level precision measurements with the IDS-iSYS 
25(OH)D assay. 
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Figure 1 A-C. Bland-Altman plots of 25(OH)D assay comparisons. The mean relative bias in percent for all immunoassays compared 
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Figure 3. Box-and-whisker plot of 25(OH)D assay comparisons. 
The central boxes represent the 25th to 75th percentile range. 
The lines inside the boxes show the median value for each 
method. The straight line shows the median value as measured 
by the liquid chromatography-tandem mass spectrometry (ref-
erence method). 
Recalibrated chemiluminescence immunoassay - IDS-iSYS 
25(OH)DS assay, IQR - interquartile range. ng/mL x 2.5 = nmol/L.
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Figure 2 A-C. Deming regression plots of 25(OH)D assay com-
parisons. Bold lines represent Deming regression lines. The re-
gression equation with the included 95% confidence intervals 
for the slope and intercept is presented next to the regression 
lines. 
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Precision studies of the LC-MS/MS method
The results of the precision studies of the LC-MS/
MS method are shown in Table 2. All within-run 
and between-run precision measurements of 
each 25(OH)D2 and 25(OH)D3 concentration level 
had a CV of ≤ 10%. 
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25(OH)D2 and C3-epimer detection by the 
LC-MS/MS method
In all blood samples (N = 198), no 25(OH)D2 and no 
C3-epimer were detected with the LC-MS/MS 
method.
Discussion
The present study compared one previous version 
and three new recently released NIST-SRM aligned 
25(OH)D assays. Compared to the NIST-SRM 
aligned LC-MS/MS method, the new IDS-iSYS 
25(OH)DS CLIA demonstrated a lower mean bias 
(16.3%) than the new ORGENTEC 25(OH)D3/D2 ELI-
SA (17.8%). In addition, Deming regression analy-
ses of the recalibrated IDS-iSYS 25(OH)DS and the 
ORGENTEC 25(OH)D3/D2 assay showed propor-
tional differences, when compared to the refer-
ence method. The IDS-iSYS 25(OH)D CLIA showed 
the lowest mean bias (1.5%) compared to the LC-
MS/MS.
Interestingly, the previous version of the CLIA (not 
aligned to the NIST-SRM) showed the better agree-
ment with the reference method compared to the 
NIST-SRM aligned immunoassays, expecting that 
the standardization of 25(OH)D assays would rep-
Assay QC material*
Within-run Between-run
Mean (ng/mL)† SD‡ CV (%)§ Mean (ng/mL) SD CV (%)
IDS-iSYS 25(OH)D
Low-level 7.7 1.2 15.5 9.4 1.8 19.1
Mid-level 38.8 3.9 10.5 3.9 3.9 10.0
High-level 66.8 4.1 6.1 65.5 4.9 7.4
IDS-iSYS 25(OH)DS
Low-level 15.2 2.9 19.0 9.8 1.6 16.3
Mid-level 48.7 4.5 9.0 49.5 5.5 11.1
High-level 78.1 5.9 7.5 78.2 6.8 8.6
ORGENTEC 25(OH)D3/D2
Low-level 19.2 1.2 6.3 16.6 1.1 6.6
Mid-level 38.8 4.8 12.3 35.6 2.1 5.8
High-level 60.3 3.6 5.9 62.3 1.9 3.0
*Quality control material of the assay manufacturers; †mean concentration in nanograms per milliliter (ng/mL x 2.5 = nmol/L); 
‡standard deviation; §coefficient of variation in percent. 





Mean (ng/mL)† SD‡ CV (%)§ Mean (ng/mL) SD CV (%)
25(OH)D2
Pool 1 10.3 0.8 7.4 9.5 0.8 5.1
Pool 2 20.1 1.4 6.9 19.2 1.4 5.1
Pool 3 27.8 1.7 6.0 24.9 1.7 3.9
25(OH)D3
Pool 1 11.5 0.8 8.7 10.7 0.9 8.8
Pool 2 21.6 1.4 7.3 21.2 1.4 6.4
Pool 3 32.3 1.7 6.9 31.5 1.5 4.7
*Three serum pools mixed with different 25(OH)D2 (25[OH]D2 spiked) and 25(OH)D3 concentration levels; †mean concentration in 
nanograms per milliliter (ng/mL x 2.5 = nmol/L); ‡standard deviation; §coefficient of variation in percent.
Table 2. Precision studies for the LC-MS/MS (reference method).
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resent an improvement of inter-assay accordance 
in daily clinical 25(OH)D determination. Consider-
ing the results of this work, it cannot be recom-
mended, that only NIST-SRM aligned methods 
should be used for routine 25(OH)D measure-
ments.
However, recent studies with commercially availa-
ble 25(OH)D assays before standardization have 
reported significant bias between 25(OH)D assays 
(19,20). For example, one immunochemical meth-
od performed on the Architect i2000 (Abbott 
GmbH, Vienna, Austria) showed a mean bias of 
27.0% compared to the LC-MS/MS method (19). 
Furthermore own published data of a previous 
work presented a significant negative absolute 
mean bias of -22.8 nmol/L between the Cobas® Vi-
tamin D3 assay (Roche Diagnostics GmbH, Man-
nheim, Germany) and the LC-MS/MS method, 
leading to a misjudgment of the actual 25(OH)D 
status of a patient (21). Meanwhile the manufactur-
er has withdrawn this assay from the market. High 
inter-assay disagreement in the 25(OH)D measure-
ments (20,22) can lead to an underestimation (23) 
or overestimation (24) of the 25(OH)D serum-lev-
els. The lack of standardization, matrix effects, 
poor antibody specificity, and cross-reactivity with 
other 25(OH)D metabolites could be possible rea-
sons for reported high inter-assay disagreement 
before standardization (21). 
The C3-epimer is one of the vitamin D metabolites, 
which is considered to be a potential confounder 
in 25(OH)D measurements, especially in infants 
(16). In the present study, no newborns or young 
children were included. Although the C3-epimer is 
also described in adults (25,26), no C3-epimer was 
detected with the LC-MS/MS method. 
Not only the C3-epimer but also other vitamin D 
metabolites are considered as possible reasons for 
significant inter-assay differences of previous pub-
lished 25(OH)D comparative studies. Many chemi-
luminescence assays use antibodies to measure 
25(OH)D in unextracted serum. These antibodies 
also recognize other vitamin D metabolites, such 
as 24, 25(OH)2D. Such assays not only provide the 
total 25(OH)D but also include the metabolites 
(27,28). Furthermore, some of these assays do not 
always recognize 25(OH)D2 and 25(OH)D3 (27). An 
increased antibody specificity could be one po-
tential reason for the improvement of the repro-
ducibility and comparability of the new NIST SRM 
aligned 25(OH)D assay generation.
According to the literature (18), the within-run and 
between-run precision goal for each concentra-
tion level of this method evaluation study was a 
CV of ≤ 20%. Based on these criteria, all evaluated 
25(OH)D methods demonstrated acceptable with-
in- and between-run precision measurements. 
The poorest within-run precision with a CV of 
19.0% was observed at the low-level precision 
measurements with the IDS-iSYS 25(OH)DS and 
the highest between-run CV with 19.1% was 
shown at the low-level precision measurements 
with the IDS-iSYS 25(OH)D assay. The low level pre-
cision measurements were performed close to the 
detection limits (IDS-iSYS 25[OH]DS assay: 7 ng/
mL; IDS-iSYS 25[OH]D assay: 5 ng/mL; ORGENTEC 
25(OH)D3/D2 assay: 5 ng/mL) of these immunoas-
says. Consequently, the precision measurements 
at this concentration levels demonstrated the 
highest CV values. Using the imprecision data in 
the light of total error, additional error sources, 
which can affect the 25(OH)D measurements in 
daily practice, must be considered. Matrix effects 
could be one additional component of error, 
which affect individual patient samples in 25(OH)D 
assays. It is caused by interfering substances pre-
sent in the sample assay tubes, which are not pre-
sent in the standard assay tubes (21). In the present 
study, it was shown that biases still exist between 
different measurement principles and procedures 
after standardization.
Since the LC-MS/MS is considered to distinguish 
25(OH)D2 and 25(OH)D3, we performed a different 
protocol for precision studies of this method (18). 
We used three serum pools (mixed with 25[OH]D2 
and 25[OH]D3) of three different concentration lev-
els to evaluate the distinction and reproducibility 
of the 25(OH)D2 and 25(OH)D3 detection of this 
commercially available 25(OH)D assay. All within-
run and between-run precision measurements of 
each 25(OH)D2 and 25(OH)D3 concentration level 
had a CV of ≤ 10%.
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In comparative studies, the LC-MS/MS is widely 
used as the reference method (12). It is a reliable 
diagnostic tool and able to distinguish 25(OH)D2 
and 25(OH)D3 (9,29). A low batch-to-batch varia-
tion and a low limit of detection are further advan-
tages of this method (30). In the present study, we 
used an LC-MS/MS method, which has met the 
performance target set by the international 
DEQAS Advisory Panel in 2013 and 2014 (data not 
shown). The method was aligned to the NIST SRM 
972a and enabled the separation and qualitative 
detection of the C3-epimers in a single analytical 
run. Nevertheless the biggest problem in 25(OH)D 
measurements in the last few years was the lack of 
a common standard. Furthermore not all LC-MS/
MS methods used in previous comparative studies 
(20) could separate C3-epimers. The LC-MS/MS 
method in particular was recommended to be 
aligned to the NIST SRM and to be able to discrimi-
nate the C3-epimer (10,20). The strength of this 
study is that these recommendations of the VSDP 
have been completely fulfilled. The reported new 
generation of 25(OH)D assays (except the previous 
used IDS-iSYS 25[OH]D assay) tested are aligned to 
the NIST SRM 2972 or 972a. 
The limitation of this study is that the precision 
studies of the immunoassays and the precision 
studies of the LC-MS/MS method were not per-
formed with the same protocol. Therefore, the 
within-run and between-run precision measure-
ments of the immunoassays are not comparable 
with the LC-MS/MS method.
In conclusion, the new generation of the NIST SRM 
aligned immunoassays and LC-MS/MS evaluated 
in this study are useful methods for measuring 
25(OH)D serum-levels in clinical laboratories. The 
performance characteristics are suitable for rou-
tine diagnostic purposes.
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